ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

FTC Seeks Additional Info From Teva, Cephalon Regarding Merger

DOW JONES NEWSWIRES Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) and acquisition target Cephalon Inc. (CEPH) each received a request to provide additional information to the U.S. Federal Trade Commission related to a pending $6.8 billion deal between the firms. Israel-based Teva, which trumped a hostile offer from Valeant Pharmaceuticals International Inc. (VRX) in agreeing to buy Cephalon last month, said it had expected the request. The parties have been cooperating with the FTC staff since shortly after the bid was announced, according to Teva, which said it intends to win clearance "as promptly as possible." Teva on Monday said it continues to expect the deal to be completed in the third quarter, following clearance from U.S. and European regulators, as well as winning approval of Cephalon shareholders. Teva's American depositary shares were recently up 0.4% to $49.35 in after-hours trading. -By John Kell, Dow Jones Newswires; 212-416-2480; [email protected]

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
01/17/201718:19:00Allergan Admits to Disclosure Violations During Valeant Bid
01/11/201703:03:00Valeant Sheds Assets to Pay Down Debt -- WSJ
01/11/201703:03:00L'Oréal Expands Its Strategy -- WSJ
01/10/201717:11:00Current Report Filing (8-k)
01/10/201716:13:52Current Report Filing (8-k)
01/10/201714:31:00Valeant to Sell Skin-Care Brands to L'Oreal -- 2nd Update
01/10/201709:13:00L'Oréal Looks to Gain U.S. Share by Buying Valeant Brands...
01/10/201708:38:00L'Oréal Looks to Gain U.S. Share by Buying Valeant Brands
01/10/201706:00:00Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb...
01/10/201706:00:00Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study...
01/10/201706:00:00Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb...
01/10/201706:00:00Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study...
01/10/201704:30:00Valeant to Sell Skincare Brands to L'Oreal -- Update
01/10/201703:41:00L'Oreal to Buy 3 Skincare Brand from Valeant for $1.3 Billion
01/10/201703:17:00Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To...
01/10/201703:17:00Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To...
01/10/201703:02:00Valeant Agrees To Sell Dendreon -- WSJ
01/09/201723:49:00Valeant Agrees to Sell Dendreon to Sanpower for $820 Million
01/09/201722:40:00Valeant To Sell Dendreon To Sanpower Group For $819.9 Million...
01/09/201722:40:00Valeant To Sell Dendreon To Sanpower Group For $819.9 Million...

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US